The Effect of Melatonin and Vitamin C on COVID-19

Lancaster General Hospital122 enrolled

Overview

This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

TRIPLE

Enrollment

122

Conditions

Covid19 SARS-CoV Infection

Interventions

Vitamin CDIETARY_SUPPLEMENT

1000mg Vitamin C, at bedtime

melatoninDIETARY_SUPPLEMENT

10mg melatonin, at bedtime

PlaceboDIETARY_SUPPLEMENT

Placebo at bedtime

Symptom Survey

Eligibility

Sex: ALLMin age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria * COVID-19 positive test (outpatient testing), * Age \>50 (chosen based greater risk for older patients to be vitamin deficient, age \>65 not used so as not to be too restrictive in the inclusion criteria) * Experiencing symptoms for \<5 days prior to enrollment * Able to read and write in English or Spanish * Able to access REDCap daily * Valid email address * Current has a Lancaster General Health primary care physician Exclusion Criteria * COVID-19 test ordered pre-procedure for asymptomatic screening * Currently taking vitamin C supplements * Currently taking melatonin supplements * Currently hospitalized * Deceased * Currently pregnant * Currently incarcerated

Locations (1)

Lancaster General Health

Lancaster, Pennsylvania, United States

Outcomes

Primary Outcomes

Symptom Severity

Symptom severity will be tracked electronically

Time frame: 14 days

Secondary Outcomes

Symptom progression

Determine symptom course of those with moderate or severe symptoms

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.